214 related articles for article (PubMed ID: 28403779)
1. Design, Synthesis and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia.
Waechter F; da Silva GNS; Willig JB; de Oliveira CB; Vieira BD; Trivella DBB; Zimmer AR; Buffon A; Pilger DA; Gnoatto SCB
Anticancer Agents Med Chem; 2017; 17(13):1777-1785. PubMed ID: 28403779
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antileukemic activity of an ursolic acid derivative: A potential co-drug in combination with imatinib.
da Silva EF; de Vargas AS; Willig JB; de Oliveira CB; Zimmer AR; Pilger DA; Buffon A; Gnoatto SCB
Chem Biol Interact; 2021 Aug; 344():109535. PubMed ID: 34051208
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and cytotoxicity of triterpenoids derived from betulin and betulinic acid via click chemistry.
Shi W; Tang N; Yan WD
J Asian Nat Prod Res; 2015; 17(2):159-69. PubMed ID: 25379995
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer activity of novel betulinic acid and betulin derivatives.
Kommera H; Kaluderović GN; Kalbitz J; Paschke R
Arch Pharm (Weinheim); 2010 Aug; 343(8):449-57. PubMed ID: 20726008
[TBL] [Abstract][Full Text] [Related]
6. Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
Lu T; Wei D; Yu K; Ma D; Xiong J; Fang Q; Wang J
Ann N Y Acad Sci; 2020 May; 1467(1):77-93. PubMed ID: 31930541
[TBL] [Abstract][Full Text] [Related]
7. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
[TBL] [Abstract][Full Text] [Related]
8. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of betulinic acid derivatives with activity against human melanoma.
Kim DS; Pezzuto JM; Pisha E
Bioorg Med Chem Lett; 1998 Jul; 8(13):1707-12. PubMed ID: 9873420
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid.
Santos RC; Salvador JA; Marín S; Cascante M; Moreira JN; Dinis TC
Bioorg Med Chem; 2010 Jun; 18(12):4385-96. PubMed ID: 20494586
[TBL] [Abstract][Full Text] [Related]
11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
Bi Y; Xu J; Wu X; Ye W; Yuan S; Zhang L
Bioorg Med Chem Lett; 2007 Mar; 17(5):1475-8. PubMed ID: 17275295
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
14. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
15. A 3D-QSAR Study on Betulinic Acid Derivatives as Anti-Tumor Agents and the Synthesis of Novel Derivatives for Modeling Validation.
Ding W; Zhang S; Zhu M; Wang S; Xu T; Qu H; Yu T; Yan X; Wang Y
Anticancer Agents Med Chem; 2017; 17(4):566-575. PubMed ID: 27658994
[TBL] [Abstract][Full Text] [Related]
16. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cytotoxic activity of heterocyclic ring-substituted betulinic acid derivatives.
Kumar V; Rani N; Aggarwal P; Sanna VK; Singh AT; Jaggi M; Joshi N; Sharma PK; Irchhaiya R; Burman AC
Bioorg Med Chem Lett; 2008 Sep; 18(18):5058-62. PubMed ID: 18752941
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and studies of anticancer properties of lupane-type triterpenoid derivatives containing a cisplatin fragment.
Emmerich D; Vanchanagiri K; Baratto LC; Schmidt H; Paschke R
Eur J Med Chem; 2014 Mar; 75():460-6. PubMed ID: 24561674
[TBL] [Abstract][Full Text] [Related]
19. New ursolic and betulinic derivatives as potential cytotoxic agents.
Baglin I; Poumaroux A; Nour M; Tan K; Mitaine-Offer AC; Lacaille-Dubois MA; Chauffert B; Cavé C
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):111-7. PubMed ID: 12943194
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of A-seco derivatives of betulinic acid with cytotoxic activity.
Urban M; Sarek J; Klinot J; Korinkova G; Hajduch M
J Nat Prod; 2004 Jul; 67(7):1100-5. PubMed ID: 15270560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
